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Simple Summary: The LI-RADS system is nowadays the mainstream system used in classifying 
liver nodules in cirrhotic liver according to their risk of malignancy. Two main LI-RADS documents 
have been released—the CEUS LI-RADS v2017 document, and the CT/MRI LI-RADS v2018 docu-
ment. In some circumstances, a nodule can be differently classified when using CEUS versus when 
using CT or MRI. In this paper, we also focus on the existing similitudes between the two documents 
but, essentially, on the differences between the two main documents and the complementarities 
between imaging techniques in characterizing liver nodules in cirrhotic livers. Awareness of the 
complementarity of imaging techniques may lead to an improvement in the characterization and 
classification of liver nodules and will reduce the number of liver biopsies. This paper proposes 
practical solutions in order to better classify and manage observations or nodules detected in cir-
rhotic livers. 
Abstract: Different LI-RADS core documents were released for CEUS and for CT/MRI. Both docu-
ments rely on major and ancillary diagnostic criteria. The present paper offers an exhaustive com-
parison of the two documents focusing on the similarities, but especially on the differences, com-
plementarity, and added value of imaging techniques in classifying liver nodules in cirrhotic livers. 
The major diagnostic criteria are defined, and the sensitivity and specificity of each major diagnostic 
criteria are presented according to the literature. The existing differences between techniques in 
assessing the major diagnostic features can be then exploited in order to ensure a better classification 
and a better clinical management of liver nodules in cirrhotic livers. Ancillary features depend on 
the imaging technique used, and their presence can upgrade or downgrade the LI-RADS score of 
an observation, but only as far as LI-RADS 4. MRI is the imaging technique that provides the great-
est number of ancillary features, whereas CEUS has fewer ancillary features than other imaging 
techniques. In the final part of the manuscript, some recommendations are made by the authors in 
order to guidephysicians as to when adding another imaging technique can be helpful in managing 
liver nodules in cirrhotic livers. 
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According to current guidelines, hepatocellular carcinoma (HCC) can be diagnosed 
in patients with cirrhosis based solely on radiologic hallmarks, without the need for his-
tologic confirmation [1,2]. The liver imaging reporting and data system (LI-RADS) was 
created to standardize liver imaging and reporting in patients at risk for HCC. It assigns 
probabilities for a nodular hepatic lesion to be HCC, benign, or non-HCC malignancy. 
The LI-RADS criteria are in use for contrast-enhanced computed-tomography (CT), con-
trast enhanced magnetic resonance imaging (MRI) (Figure 1), and contrast enhanced ul-
trasound (CEUS) (Figure 2). Different core documents were issued for CT/MRI and, CEUS, 
respectively [3,4]. The last CEUS-LIRADS version was released in 2017, whereas the last 
LI-RADS version for CT/MRI was released in 2018. Both documents describe major and 
ancillary imaging features (AF) of HCC in cirrhotic patients. CEUS-LI-RADS is only con-
sidered appropriate for HCC diagnosis, whereas CT/MRI LI-RADS can be used for both 
diagnosis and staging of HCC [3,4]. 
 
Figure 1. CT/MRI LI-RADS diagnostic table, adapted from CT/MRI LI-RADS® v2018 core doc-
ument. * LR-4 if the one additional feature is an enhancing capsule, otherwise, LR-5; APHE—
arterial phase hyperenhancement (as defined within the text, non-peripheral). 
 
Figure 2. CEUS LI-RADS diagnostic table, adapted from CEUS LI-RADS® v2017 core document. 
APHE—arterial phase hyperenhancement (as defined within the text, not rim, nor peripheral dis-
continuous globular). 
For CT and MRI, the 2018 version of LI-RADS brings the following as new elements 
(as compared to the 2017 version): 
• Threshold growth, a major diagnostic criterion, has a simplified definition in the lat-
est document. Now, it only refers to an increase in size of over 50% of an observation 
in less than 6 months. A new observation of ≥10mm, or a ≥100% increase in size of an 
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observation over more than 6 months are now considered criteria for subthreshold 
growth, which represents an ancillary feature. 
• In order to simplify the LI-RADS algorithm, LI-RADS 5g and LI-RADS 5us categories 
were eliminated. In practice, this refers to observations with arterial phase hyperen-
hancement (APHE), with a size ≥10 mm and ≤19 mm. In the previous 2017 version, 
ultrasound visualization of a nodule was necessary for observations measuring 10 to 
19 mm with APHE and non-rim washout in order to categorize the observation as 
LI-RADS 5 (LI-RADS 5us). If the observation was not visible by ultrasound, the nod-
ule was classified as LI-RADS 4. In the new document, every observation measuring 
10 to 19 mm with APHE and non-rim washout can be classified as LI-RADS 5. Ob-
servations with a size ≥10 mm and ≤19 mm with APHE and threshold growth (de-
fined as the mentioned above) are now classified as LI-RADS 5, not LI-RADS 5g, as 
previously. Observations measuring 10 to 19 mm with APHE and an enhancing cap-
sule, and with no non-rim washout and/or threshold growth, are classified in both 
documents as LI-RADS 4 [5]. 
This paper compares the two main LI-RADS core documents, highlighting similari-
ties and differences between them. Situations when imaging techniques are complemen-
tary are also highlighted and improvements in the classification of liver nodules after the 
combined use of imaging techniques are suggested. All the major and some of the ancil-
lary HCC features will be discussed and presented from both documents’ perspective. 
In the literature, there are other papers comparing LI-RADS CEUS 2017 with the pre-
vious LI-RADS CT/MRI document. [6,7]. However, they more on the differences between 
the two main documents and not on their complementarity nor on the added value of 
imaging techniques, which are the focus of the current paper. 
Some scientific papers focus on the contribution of CEUS to accurately classify inde-
terminate observations on CT/MRI or hypovascular nodules with a LI-RADS 3 or LI-
RADS 4 appearance on sectional imaging [8,9]. However, as far as we know, our current 
paper is the first one exhaustively comparing the two LI-RADS core documents by com-
paring the reported accuracy of techniques in assessing each major and each ancillary fea-
ture that is common in both documents. Moreover, we propose practical solutions derived 
from the complementarity of the imaging techniques (CEUS versus CT/MRI) in order to 
better classify and manage observations or nodules detected in cirrhotic livers. 
2. Observation or Focal Liver Lesion 
2.1. Definition 
Firstly, we need to introduce the LI-RADS term “observation”, which is a distinctive 
area compared to the background liver at imaging [10]. An observation may represent a 
true lesion (if there is a corresponding pathologic abnormality) or a pseudolesion (if there 
is not). The term “observation” only applies to CT and MRI, but not to CEUS. As a generic 
LI-RADS term, it is preferred over focal liver lesion (FLL) or nodule, since some observa-
tions (e.g., perfusion alterations, artifacts) may represent pseudolesions rather than true 
lesions or nodules. In the published literature on ultrasound and CEUS, the term “obser-
vation” is rarely used. The World Federation for Ultrasound in Medicine and Biology 
(WFUMB) and European Federation of Societies for Ultrasound in Medicine and Biology 
(EFSUMB) guidelines on CEUS of the liver prefer the term “FLL” over “nodule”. 
2.2. Phases of Enhacement 
The main criterion for characterizing an FLL is its behavior following intravenous 
contrast injection. For a proper characterization of FLLs, a tri-phasic evaluation is manda-
tory: arterial, portal, and late phases are defined by the time gap between contrast injec-
tion and image acquisition. While CEUS offers a continuous, real-time evaluation of a le-
sion’s behavior, CT and MRI only immortalize static frames of multiple time-points fol-
lowing contrast injection. 
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Regardless of the technique used, the arterial phase represents the acquisition imme-
diately following the moment of contrast injection. For CT/MRI diagnosis and characteri-
zation of focal liver lesions, particularly HCC, a late arterial phase is preferred. Images are 
thus acquired 35 to 45 s after contrast media injection [3]. In CEUS, the arterial phase starts 
at 10–20 s and ends 30–45 s after contrast injection [4]. 
On CT/MRI, the portal phase is characterized by image acquisition at 60–75 s after 
contrast injection. The portal venous system is completely visualized and the liver paren-
chyma is at its peak enhancement [3]. In CEUS, the portal phase starts at 30–45 s and lasts 
for up to 120 s following contrast injection [4]. 
The late (delayed) phase image acquisition on CT/MRI occurs at any point between 
2 to 5 min following contrast administration. Contrast is still visible within the portal ve-
nous system and liver parenchyma, but is not as prominent as during the portal phase. 
With CEUS, the late phase lasts from 2 to 6 min after contrast injection [3,4]. 
Some contrast media used in MRI (called hepatobiliary agents, as their excretion is 
not only through kidney but through liver as well) can offer us a very late hepatobiliary 
phase. In this phase, the liver parenchyma enhances more than the blood vessels and the 
contrast media is also excreted into the biliary tree. 
3. Major Features 
An overview of the major LI-RADS features compared between CEUS and CT/MRI 
is presented in Table 1. 
Table 1. Major features within the CT/MRI LI-RADS® v2018 core document—summary table for 
comparison across CEUS, CT, and MRI (similarities/differences). 









Late and mild (> 60 s) 
+ 
Relative “washout” 
Regardless of intensity/onset 
Threshold growth 
Not a major feature 
CT/MRI recommended if positive 
++ 
Enhancing capsule Not appreciable +/++ 
3.1. Arterial Phase Hyperenhacement (APHE) 
3.1.1. Definition 
Arterial phase hyperenhancement (APHE) is the most important feature in charac-
terizing HCC in patients at risk for liver cirrhosis. Therefore, an observation cannot be 
defined as LI-RADS 5 without APHE, regardless of size or any other features [11]. In LI-
RADS, APHE is defined as non-rim like enhancement of the entire or part of an observa-
tion, unequivocally greater than the enhancement of the surrounding liver [12]. Rim en-
hancement and rim washout, only involving the periphery of a lesion, suggests a non-
HCC malignancy (and is therefore defined as LI-RADS M). APHE has good sensitivity for 
the diagnosis of progressed HCC (reported by different papers as ranging between 65 and 
96%), but may be absent in well-differentiated HCC [12]. Studies reporting the presence 
of APHE on CT and MRI scans of pathology-proven HCC show a rather mediocre sensi-
tivity of APHE for HCC diagnosis (74%)—which is even lower (43 to 53%) for lesions 
smaller than 1 cm [13]. 
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3.1.2. Comparison of CEUS, CECT, and MRI, Similarities and Differences 
Similarities 
In both documents, APHE is defined as greater enhancement of an observation as 
compared to the surrounding liver. APHE can be diffuse, throughout the whole observa-
tion, or limited to part of the observation. Both documents exclude rim enhancement, 
which is defined as arterial phase hyperenhancement more pronounced in the periphery 
of the lesion and suggests malignancy in general, other than HCC [12]. Peripheral discon-
tinuous globular APHE is also excluded, as it is specific for hemangiomas. 
Differences and Complementarity of Techniques 
The use of CEUS can improve the sensitivity of APHE for HCC diagnosis. CEUS pro-
vides real-time enhancement of a lesion, whereas on CT or MRI, the lesion is visualized 
in most cases during the late arterial phase only. There are several studies that have ana-
lyzed the value of adding CEUS for indeterminate, arterial phase non-hyperenhancing 
(APNHE) liver lesions at MRI or CT [14]. Their results showed that 25.9% and 27.9%, re-
spectively, of APNHE observations further presented APHE in CEUS examination, all of 
them being diagnosed as HCC [9,14]. Moreover, Takayasu et al. reported a higher sensi-
tivity of APHE for well-defined HCC on CEUS than on MRI (59.3% vs. 46.3%), while the 
results of Bolondi et al. showed that CEUS provides more sensitive detection of APHE 
than CT for HCC observations (APHE sensitivity on CEUS = 88% vs. 77% on CT) [15,16]. 
CEUS can therefore depict APHE in lesions with no definite APHE on CT and MRI (Figure 
3). Such lesions that would, at most, be characterized as LI-RADS 4 (no APHE depiction) 
on CT/MRI would be upgraded from LI-RADS 3 to 4 or from LI-RADS 4 to 5 by CEUS [6]. 
The only exception to this is a lesion less than 20 mm in size, with no other HCC feature—
which would be characterized as LI-RADS 3, irrespective of APHE presence. 
 
Figure 3. Grayscale ultrasound of the liver showing a slightly hypoechoic nodule in segment six of 
the liver in a cirrhotic patient (a). On CEUS, the nodule was hypervascular in the arterial phase (b) 
with no washout in the late phase (c), and it was consequently classified as LI-RADS 4. On CT, the 
nodule was isoenhancing to the liver parenchyma in all phases of enhancement. The nodule was a 
biopsy proven HCC. 
The presence of hypervascular pseudolesions such as arterio-portal shunts will man-
ifest on CT and MRI as APHE, lowering the specificity of APHE for HCC [17]. CEUS gen-
erally targets lesions identified on baseline ultrasound scans. Since hypervascular pseu-
dolesions are not seen on a baseline scan, they would not be depicted on CEUS. Therefore, 
the positive predictive value of CT/MRI APHE for HCC is rather mediocre (ranged be-
tween 65 and 81%) [18–20], whereas the positive predictive value of CEUS is significantly 
higher. Several studies reported a positive predictive value (PPV) value of 100% of CEUS 
APHE for the diagnosis of HCC [21,22]. Additionally, the specificity of APHE detected on 
CEUS is very high for the diagnosis of HCC, reaching 100% [21,22]. PPV and specificity 
are closely related. Consequently, any observation with APHE on CEUS measuring 10 
mm or more showing APHE is either an LI-RADS 4 or an LI-RADS 5 nodule [6]. In con-
trast, a lesion depicted on CT/MRI, measuring 10 to 20 mm with APHE only and no other 
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Washout is defined as a temporal reduction in the enhancement of an observation in 
whole or in part, relative to the surrounding liver parenchyma, from an earlier to a later 
phase, resulting in hypoenhacement [3,4]. LI-RADS prefers washout over hypoenhancing 
because the degree of enhancement of the observation during the late phases has to be 
unequivocally lower than that in the earlier phases (not only unequivocally lower than 
the enhancement of the liver parenchyma) in order to be a major LI-RADS criteria [23]. 
3.2.2. Comparison of CEUS, CECT and MRI, Similarities and Differences 
Similarities 
• Washout represents a major imaging feature in both CT/MRI LI-RADS and CEUS LI-
RADS cores, its presence excluding a LR-1 and LR-2 observation 
• However, the sole presence of washout is not sufficient for an observation to be cat-
egorized as LR-5 on either CEUS or CT/MRI. There are a few papers that investigated 
the performance of washout as a standalone feature for the diagnosis of HCC and the 
reported specificities ranged between 62–100%. Furthermore, in all of these studies, 
the combination of “washout” and APHE has proved to have higher specificity (96–
100%) and PPV (97–100%) when compared with the specificity of “washout” alone 
[24–26]. 
• On CEUS, as well as on CT/MRI, washout can be applied for any enhancing observa-
tion, even in the absence of APHE. 
Differences and Complementarity of Techniques 
Several papers showed that the presence of washout is more often encountered in 
HCC on CEUS, as compared to CT/MRI. A recent study by Wang et al. reported a washout 
appearance observed more frequently on CEUS than on CE-MRI (50% vs. 28.6%) [27]. Ad-
ditionally, the results of Hu et al. showed that 38% of HCC nodules without washout on 
MRI presented further washout when evaluated on CEUS [8]. Nodules which can be char-
acterized as LI-RADS 5 on CEUS (APHE and the presence of late and mild washout) 
would be LI-RADS 4 or even 3 at CT/MRI (due to the absence of washout). One possible 
explanation for this is the difference in contrast agents used in CEUS versus CT/MRI (Fig-
ures 4 and 5). 




Figure 4. CT scans of the liver obtained in the arterial (a) and late phases (b). The blue arrow 
shows a hypervascular nodule (a) with washout (b) localized in segment two of the liver, close to 
the left portal vein. On CT, the nodule was classified as LI-RADS 5. On US (c), the nodule (blue 
arrow) was slightly hyperechoic/isoechoic as compared to the surrounding liver parenchyma. On 
CEUS, the blue arrow shows the same nodule, which presented APHE (d) but did not show any 
washout (e), therefore, it was classified as LI-RADS 4. This is a rather atypical behavior, as wash-
out is more often seen on CEUS as compared to CT/MRI. 
 
Figure 5. CT scans of the liver obtained in the arterial (a) and late phases (b). A hypervascular 
nodule (blue arrow) is seen in segment eight of the liver (a). In the late phase (b), the nodule be-
comes isoenhancing to the liver parenchyma (blue arrow). The nodule was consequently classified 
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as LI-RADS 4 on CT. On US (c), the nodule was slightly hypoechoic/isoechoic (blue arrow) as com-
pared to the surrounding liver parenchyma. On CEUS, the nodule (blue arrow) presented APHE 
(d) and late and mild washout (e), and was classified as LI-RADS 5. 
Ultrasound contrast is a pure “blood pool” agent, which remains intravascular, not 
passing the vascular endothelium [28]. On the other hand, CT/MRI contrast agents can 
extravasate into the tumor interstitium, resulting in the gradual enhancement of malig-
nant lesions during the late phase [29–31]. There are several differences between the 
CT/MRI LI-RADS core and the CEUS LI-RADS core concerning the presence or absence 
of washout: 
• Washout versus “washout” 
CEUS LI-RADS core uses the term washout for characterizing an observation that 
reduces its enhancement, while on CT/MRI LI-RADS core, the correct term is “washout”. 
This difference happens since, on CEUS, the washout phenomenon is a true one, while on 
CT/MRI, the washout of an observation may only be apparent, and can actually be the 
result of an increased enhancement of surrounding liver tissue, rather than an actual re-
duction in a nodule enhancement. 
• The characterization of washout by its onset and degree 
CEUS LI-RADS document divides washout into (a) late (>60 s) and mild washout (its 
presence is a major criterion for HCC) and (b) early (<60 s) and/or strong washout (which 
categorizes a liver observation as LI-RADS M or non-HCC malignancy). Conversely, 
washout is a major HCC criterion on CT/MRI regardless of its intensity or onset. In the 
last few years, there have been several published papers that investigated the importance 
of washout onset and degree for the differentiation between HCC and other malignancies 
in CEUS [12,32–36]. All these studies reported that the majority of intrahepatic cholangi-
ocarcinoma (ICC) or other non-HCC malignancies showed an early and marked washout, 
usually within 1 min after contrast injection, while the majority of HCC were character-
ized by a late and mild washout. Moreover, Terzi et al. demonstrated that if the washout 
criterion was applied based only on its presence and regardless of its onset and degree, 
the PPV for HCC would have been lower: 94% versus 98.5% [37]. 
Therefore, in CEUS LI-RADS core, an observation should be categorized as LI-RADS 
M (LR-M) if it has one of the following features: rim APHE or early or marked washout. 
However, it should be noted that all LR-M lesions should be histologically proven. Still, a 
significant percentage (48%) of LR-M lesions on CEUS are atypical HCC at biopsy, rather 
than non-HCC malignancies [6]. 
• The characterization of washout by its spatial pattern 
In CT/MRI LI-RADS document, “washout” as a major imaging feature specific for 
HCC, which requires the presence of a non-peripheral temporal reduction in enhance-
ment in a liver observation, while a peripheral “washout” is a characteristic feature for 
LR-M lesions. In CEUS LI-RADS, the washout criterion does not mention its localization 
within the liver observation. 
This difference occurs because of the type of contrast agents used for the imaging 
modalities and their different tissue behavior and kinetics. The purely intravascular con-
trast microbubbles used for CEUS are drained rapidly from all tumor compartments, in-
cluding the fibrotic center of ICC, resulting in a hypoechoic appearance of the entire liver 
observation, regardless of its tissue components. Conversely, the contrast agents used for 
CT/MRI drain rapidly from the arterialized, peripheric part of a lesion, but they accumu-
late gradually into the centrally located interstitium. The ICC and other non-hepatocellu-
lar malignancies with a central fibrotic component will appear as targetoid observations 
with peripheral hypoenhancement and central delayed enhancement [38–42]. However, 
the peripheral “washout” is encountered especially in ICCs >3 cm, while the small ICCs 
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often exhibit non-peripheral “washout” [43–45]. Moreover, some HCCs may present pe-
ripheral “washout”. Therefore, the differential diagnosis based only on this spatial crite-
rion may be sometimes difficult. 
3.3. Threshold Growth 
3.3.1. Definition 
The definition for threshold growth was simplified in version 2018 of the CT/MRI 
core document, achieving concordance with American Association for the Study of Liver 
Diseases (AASLD) and Organ Procurement and Transplantation Network (OPTN) defini-
tions. Threshold growth is clearly defined as an increase in size ≥50% in ≤6 months, and it 
only represents a major feature favoring malignancy in the CT/MRI LI-RADS core docu-
ment, but not in the CEUS core document. 
3.3.2. Comparison of CEUS, CECT, and MRI, Similarities and Differences 
Similarities 
Growth is viewed and defined differently within the two core documents. Regardless 
of the imaging techniques used, the radiologist should use the same plane as prior exam 
to assess growth, on the same imaging mode in CEUS (or B-mode ultrasound) and the 
same phase and sequence on serial imaging (CT/MR). 
Differences and Complementarity of Techniques 
Regarding the threshold growth, there are the following differences between CT/MRI 
LI-RADS and CEUS LI-RADS core documents: 
• Threshold growth is a major feature for HCC in the CT/MRI LI-RADS core document, 
but only an ancillary feature suggesting malignancy in the CEUS core document. 
• Definite growth is defined by the CEUS LI-RADS core document as the unequivocal 
increase in size of a lesion; there is no established “threshold”, but >5 mm is generally 
considered unequivocal growth. Ultrasound should only be compared with ultra-
sound and the size increase should not be attributable to artifacts, measurement er-
rors, or difference in technique [46]. 
• Unequivocal growth evaluated by CEUS favors malignancy in general, not HCC in 
particular (as threshold growth does in CT/MRI). 
• Using the arterial phase of enhancement when measuring an observation should be 
avoided, if possible, on CT/MRI due to the risk of overestimating the lesion size. On 
CEUS, measuring the observation can, in most cases, only been done in the arterial 
phase. On CT/MRI, an observation should be measured in the phase, sequence, and 
plane in which its margins are the most clear. In the meantime, measuring a lesion in 
the arterial phase or on diffusion weighted imaging should be avoided [47]. 
• Threshold growth is considered of less importance in CEUS as compared to CT/MRI. 
This is because of the lesser reproducibility of US images as compared to CT/MRI 
and the difficulties of obtaining the same plane of the lesion on seriate US examina-
tions [6]. 
Increase in size of a lesion is a criterion with good specificity for the diagnosis of 
HCC, threshold growth (evaluated by CT/MRI) having high specificity—between 83–85% 
[48]. This means that if one nodule increases in size more than 50% over less than 6 
months, it is much more likely to be HCC. Various studies reported HCC tumor volume 
doubling time ranging from as low as 9 days [11] to more than a year [49–51]. The growth 
rate depends on the degree of differentiation; well-differentiated HCC tends to grow 
slower, while moderate and poor differentiated HCC have shorter doubling times [52–
54]. However, any increase in size of a nodule is considered an ancillary feature on CEUS 
examination [4]. Therefore, we recommend associating CT or MRI in every patient in 
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which US/CEUS suggests increase in size of a nodule—unequivocal threshold growth as-
sociated with APHE can classify the nodule as LI-RADS 5 and biopsy can be avoided. 
3.4. Enhancing Capsule 
An enhancing capsule is a major diagnostic feature in the CT/MRI core but not in the 
CEUS core. Capsule presence is defined as a uniform, sharp border, thicker than the fi-
brotic tissue of the background nodules, which is detected as an enhancing rim in the 
portal, late, or transitional phase [12]. A capsule should be differentiated from “rim en-
hancement”, which is characteristic for LI-RADS M: rim enhancement is typically pro-
nounced in the arterial phase with later washout, whereas a capsule is enhanced in the 
portal or late phase and is enhanced less or equally than the surrounding liver in the early 
phases [55]. The differences between CEUS and CT/MRI in depicting the capsule may be 
due to the fibrotic content of the capsule as CT/MRI contrast media will diffuse into inter-
stitial tissue, in contrast to ultrasound contrast media, which remains strictly intravascu-
lar. 
According to previous MRI studies, the presence of an enhancing capsule has 
low/moderate sensitivity, ranging between 32.9–55%, and very high specificity, within the 
range of 83–98.8% for the diagnosis of HCC [26,56,57]. Regarding the differences between 
CT and MRI, Zhang et al. showed that, when compared to MRI, CT produced false-nega-
tive findings of a pseudocapsule by 42.9%, thus underestimating the LI-RADS score of 
liver lesions [58]. Additionally, the study of Corwin et al. revealed that nearly half of the 
liver observations had the LI-RADS category upgraded upon MRI compared with CT, one 
of the reasons for this being the visualization of a delayed enhancing capsule on MRI, 
which was not seen on CT [59]. Another study, which evaluated the value of LI-RADS 
features on contrast-enhanced CT for the diagnosis of HCC, showed that an enhancing 
capsule had the lowest sensitivity (20.7%) among the major features [48]. 
4. Ancillary Features 
4.1. Definition 
Ancillary features (AF) are imaging features, which modify an observation’s likeli-
hood of being HCC. AF favoring HCC can upgrade the LI-RADS score of an observation 
by one category, up to LI-RADS 4. AF cannot upgrade an observation from LI-RADS 4 to 
LI-RADS 5; therefore, for LI-RADS 5, a combination of major features is needed. AF fa-
voring benignity will downgrade the LI-RADS score by one category. The absence of AF 
favoring malignancy or benignity should not be used neither to downgrade nor upgrade 
the LI-RADS score, respectively. 
4.2. Comparison of CEUS, CECT and MRI, Similarities and Differences 
The similarities and differences between AF that can be evaluated on both CEUS and 
CT/MRI are summarized in Table 2. 
Table 2. Ancillary features (AF) presented in the CEUS LI-RADS® v2017 and CT/MRI LI-RADS® 
v2018 core documents—summary table for comparison across CEUS, CT, and MRI (similari-
ties/differences). AF only assessable by CT/MRI were not included in this table. 
  CEUS CT MRI 
Favoring HCC 
Mosaic appearance + + ++ 










Size stability >2 years + + + 
Size reduction + + + 




Although AF differ depending on the modality used, the way they are applied to 
modify the LI-RADS score is similar for CEUS, CT, or MRI. AF are to be used at the radi-
ologist’s discretion for improved detection, increased confidence, or category adjustment. 
An ancillary feature should be characterized as absent if its presence is uncertain. AF fa-
voring benignity will downgrade the LI-RADS score by one category, while AF favoring 
malignancy will upgrade the score by one category. The LI-RADS score cannot be up-
graded to 5 with AF in either technique [3,4]. 
Ancillary features are classified, in both documents, in the following: 
- AF favoring malignancy in general 
- AF favoring HCC in particular 
- AF favoring benignity 
The ancillary features which are common for the two documents are as follows: 
- The mosaic architecture and nodule in nodule (both considered AF which favor HCC 
in particular) 
- Stability in the size of an observation ≥2 years in the absence of treatment or unequiv-
ocal decrease in size of a lesion (both considered as AF favoring benignity) 
Mosaic appearance and nodule in nodule architecture are AF in both core documents. 
Nodule in nodule architecture is considered to be a subtype of mosaic appearance [45]. 
Mosaic architecture refers to the presence of randomly distributed internal nodules and 
compartments inside a liver nodule, usually with different imaging features. Heterogene-
ity of a liver mass is more easily depicted on MRI as compared with CT/CEUS, and on MR 
T2 weighted sequences as compared to T1 weighted sequences. A mosaic pattern is seen 
in 28–63% of HCC nodules with a size greater than 3 cm [60]. 
The nodule in nodule architecture corresponds to the presence of a smaller, inner 
nodule with different imaging features than the larger outer nodule [61]. In many cases, a 
nodule in nodule appearance can correspond to a smaller HCC nodule developing into a 
bigger dysplastic nodule [62]. 
If the inner nodule (in the case of nodule in nodule “architecture”) or one part of the 
inner structure of the lesion displays LI-RADS 5 features (such as APHE and washout), 
the whole observation should be considered LI-RADS 5 and the aspect should not be in-
terpreted as an ancillary feature [63] (Figure 6). 
 
Figure 6. MRI of the liver. Nodule in segment seven (red arrow), which shows progressive en-
hancement in the arterial (a), portal (b), and late phase (c). The nodule was classified as LI-RADS 
M on MRI and the radiologist suspected a cholangiocarcinoma. On CEUS, the lesion had a “nod-
ule in nodule” architecture and the inner nodule showed APHE and washout, and the nodule was 
classified as LI-RADS 5. 
4.2.2. Differences 
AF differ depending on the modality used. 
Regarding LI-RADS score assessment, CEUS provides fewer AF than other modali-
ties: 
• Interval growth of an observation 
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Unequivocal size increase is an AF that favors malignancy in general, whereas size 
stability (for at least 2 years and in the absence of treatment) or unequivocal size reduction 
of a lesion are AF which favor benignity. 
• Nodule in nodule architecture (favors HCC) 
• Mosaic architecture (which equally favors HCC) 
The LI-RADS CT/MRI v2018 core document provides additional AF, not assessable 
by CEUS. Some of those features can be evaluated by both CT and MRI, while others are 
applicable only to MRI. These are listed in Table 3; defining them goes beyond the scope 
of this article, and we kindly refer the reader to the CT/MRI LI-RADS v2018 core docu-
ment for that purpose [3]. 
Table 3. Ancillary features (AF) presented only in the CT/MRI LI-RADS® v2018 core document. 




US visibility as discrete 
nodule 
+ + 
Subthreshold growth + + 
Corona enhancement + + 
Fat sparing in solid mass  +/− + 












Nonenhancing “capsule” +/− + 
Fat in mass, more than ad-
jacent liver 
+/− + 
Blood products in mass +/− + 
Favoring benignity 
Parallels blood pool en-
hancement 
+ + 
Undistorted vessels + + 
Iron in mass, more than 
liver 
+/− + 




In the CEUS LI-RADS document, any increase in size of an observation is an AF fa-
voring malignancy. In the CT/MRI LI-RADS document, an increase in size of an observa-
tion is divided into the following: 
- threshold growth (increase of a mass by ≥50% in ≤6 months) 
- subthreshold growth is defined as increase in size of an observation by less than 50% 
in 6 months, by any size increase in more than 6 months, or by the appearance of a 
new lesion, regardless of its size [41]. 
A new observation in a cirrhotic liver cannot be considered HCC (LI-RADS 5) with-
out other diagnostic criteria, which may include the lesion as LI-RADS 5. On MRI exami-
nation, subthreshold growth as a standalone feature has a sensitivity of 48% and a speci-
ficity of 91% for the diagnosis of HCC [56]. A study of Alhasan et al., which evaluated the 
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diagnostic performance of LI-RADS features onCT, reported a sensibility of 50.8% and a 
specificity of 66.9% of subthreshold growth for HCC [48]. 
Ultrasound Visibility as a Discrete Nodule 
US visibility as a discrete nodule is an AF mentioned in the CT/MRI LI-RADS core 
and refers to visibility at non-enhanced US of an observation depicted by CT and MRI. As 
most of the benign lesions on a cirrhotic liver and all vascular pseudolesions are not to be 
seen, indistinguishable from the surrounding liver on B-mode ultrasound, most nodules 
seen by the means of ultrasound in a cirrhotic liver, are malignant [64]. A paper by Darnell 
et al. shows that 96% of LI-RADS 4 and 69% of LI-RADS 3 observations were HCC nodules 
if visible on ultrasound [65]. This data suggests that ultrasound visibility as a discrete 
nodule, is a strong AF favoring HCC. 
5. Summary—Complementarity and Added Value of the Techniques 
CEUS is considered appropriate for the diagnosis of HCC nodules, whereas CT/MRI 
are appropriate for both the diagnosis and staging of HCC. Even if a nodule is diagnosed 
as HCC on CEUS, a CT or MRI of the liver has to be performed before therapy in order to 
accurately stage the disease. This is due to the difficulties that US has in exploring the 
whole liver. For instance, obese or non-cooperating patients, a limited acoustic window, 
parenchymal heterogeneity, or reduced beam penetration represent possible limitations, 
which lead to inadequate evaluation of the entire liver [66]. Additionally, the location of 
the liver nodules is another concern, with two studies reporting that deep-seated, subdi-
aphragmatic lesions were difficult to visualize and assess on CEUS [67,68]. When dealing 
with multifocal disease, CEUS can only target one lesion in a short-lasting arterial phase, 
which represents another limitation of the technique. CT and MRI evaluate the whole liver 
parenchyma and multiple lesions can be characterized in a single-phase acquisition. 
Therefore, international guidelines do not recommend US or CEUS for staging HCC or 
for assessing the presence of metastasis [4]. 
• APHE is a crucial diagnostic feature of HCC. A liver nodule cannot be diagnosed by 
means of imaging as a LI-RADS 5 observation without APHE. APHE is more easily 
and accurately depicted by CEUS as compared to CT/MRI [9,14,15,29]. This means 
that, in practice, a nodule characterized as LI-RADS 3 or 4 by CT/MRI (e.g., a nodule 
without APHE presenting some washout) can be characterized as LI-RADS 5 by 
CEUS. We recommend CEUS in suspicious nodules without APHE on CT/MRI. 
• CEUS is more sensitive than CT/MRI for depicting washout. In nodules with APHE 
but without washout on CT and MRI (LI-RADS 3 or 4), CEUS can prove the presence 
of washout, upgrading the nodule to LI-RADS 5 and, by this, avoiding biopsy. We 
recommend CEUS in nodules with APHE, but without washout on CT/MRI. On the 
contrary, if the observation, presenting only with APHE on CT/MRI, is not seen on 
US/CEUS, it is more likely a vascular pseudolesion and can be confidently considered 
as benign. 
• Washout on CEUS was further divided into early and strong washout (characteristic 
of non-HCC malignancy) and late and mild washout (a major criterion for HCC). The 
rationale was improving the sensitivity of diagnosing non-HCC malignancies (par-
ticularly ICC) in cirrhotic livers. Still, by using these criteria, many atypical HCC nod-
ules will have a LI-RADS M appearance on CEUS. CT and MRI can change the LI-
RADS score for some of this nodules to LI-RADS 5 in these patients, avoiding biopsy, 
or increase confidence in the diagnosis of LI-RADS M by demonstrating other diag-
nostic features such as late phase central enhancement. 
• Increase in size of a lesion is a criterion with good specificity for the diagnosis of HCC 
[48]. Threshold growth on CT/MRI is defined by an increase in size of one nodule of 
more than 50% over less than 6 months; however, any increase in size of a nodule is 
considered an ancillary feature on CEUS examination [4]. Therefore, we recommend 
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associating CT or MRI in every patient for whom US/CEUS suggests increase in size 
of a nodule—unequivocal threshold growth associated with APHE can classify the 
nodule as LI-RADS 5 and biopsy can be avoided. 
• For mosaic and nodule in nodule lesions, if APHE cannot be demonstrated by 
CT/MRI, we recommend additional imaging by CEUS, which is more sensitive in 
depicting APHE (and subsequently possibly classifying the lesion as LI-RADS 5). 
• Ultrasound visibility of the observation as a discrete nodule is an ancillary feature, 
which helps in differentiating true hepatic lesions from vascular pseudolesions. In 
most cases, if used as an AF, it upgrades the LI-RADS score from 3 to 4. Many LI-
RADS 3 nodules and a vast majority of LI-RADS 4 nodules depicted by ultrasound 
prove to be HCC. Therefore, if a LI-RADS 3 nodule is depicted by CT or MRI and 
was not described in the screening by surveillance ultrasound, we suggest repeating 
a targeted US, as sensitivity of screening ultrasound is known to be moderate, rang-
ing between 58–94% for HCC detection at any stage [69–73], being even lower for the 
detection of early stage tumors, between 47–63% [71,72]. For LI-RADS 4 nodules, re-
peating US will not be necessary, as an ancillary feature cannot upgrade the score to 
LI-RADS 5. 
6. Conclusions 
CEUS, CT, and MRI are all established techniques in the diagnosis of focal liver le-
sions in cirrhotic livers. CEUS is appropriate only for HCC diagnosis, whereas CT and 
MRI are appropriate for both the diagnosis and staging of HCC. Nevertheless, CEUS still 
holds some advantages over CT/MRI, providing a more accurate evaluation of APHE and 
washout. Washout is divided in CEUS into strong and early washout and late and mild 
washout in order to differentiate HCC from non-HCC malignancies. On the other hand, 
the size increase of a lesion is more accurately evaluated on CT/MRI as compared to CEUS. 
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